Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Crystal L Mackall"'
Autor:
Robbie G. Majzner, Crystal L. Mackall
Publikováno v:
Nature Medicine. 25:1341-1355
Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed expectations, driving an ever-expanding number of clinical trials and the first US Food and Drug Administration approvals of cell therapies for the treatment of canc
Publikováno v:
Nature Biomedical Engineering. 2:377-391
T cells engineered to express chimeric antigen receptors (CARs) that are specific for tumour antigens have led to high complete response rates in patients with haematologic malignancies. Despite this early success, major challenges to the broad appli
Autor:
Staci Martin, Robbie G. Majzner, Constance M. Yuan, Bonnie Yates, Jack F. Shern, Haneen Shalabi, Haiying Qin, David F. Stroncek, Marianna Sabatino, Terry J. Fry, Boro Dropulic, Cindy Delbrook, Yang Feng, Nirali N. Shah, Thomas J. Fountaine, Rimas J. Orentas, Daniel W. Lee, Crystal L. Mackall, Maryalice Stetler-Stevenson, Sneha Ramakrishna, Pamela L. Wolters, Dimiter S. Dimitrov, Ling Zhang, Sang M. Nguyen
Publikováno v:
Nature Medicine. 24:20-28
Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent effects in relapsed and/or refractory pre-B cell acute lymphoblastic leukemia (B-ALL), but antigen loss is a frequent cause of resistance to CD19-targeted immunotherapy. CD22 is al
Autor:
Christine E. Brown, Crystal L. Mackall
Publikováno v:
Nature Reviews Immunology. 19:73-74
Here, we highlight key papers published in 2018 that advance our understanding of resistance to chimeric antigen receptor (CAR) T cell immunotherapy for leukaemia and lymphoma and in so doing reveal barriers that must be addressed to increase efficac